Richard S Shame - Net Worth and Insider Trading
Richard S Shame Net Worth
The estimated net worth of Richard S Shame is at least $1 Million dollars as of 2024-11-13. Richard S Shame is the Chief Medical Officer of Protagonist Therapeutics Inc and owns about 32,021 shares of Protagonist Therapeutics Inc (PTGX) stock worth over $1 Million. Details can be seen in Richard S Shame's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Richard S Shame has not made any transactions after 2019-03-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Richard S Shame
Richard S Shame Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Richard S Shame owns 1 companies in total, including Protagonist Therapeutics Inc (PTGX) .
Click here to see the complete history of Richard S Shame’s form 4 insider trades.
Insider Ownership Summary of Richard S Shame
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2019-03-01 | Chief Medical Officer |
Richard S Shame Latest Holdings Summary
Richard S Shame currently owns a total of 1 stock. Richard S Shame owns 32,021 shares of Protagonist Therapeutics Inc (PTGX) as of March 1, 2019, with a value of $1 Million.
Latest Holdings of Richard S Shame
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2019-03-01 | 32,021 | 42.68 | 1,366,656 |
Holding Weightings of Richard S Shame
Richard S Shame Form 4 Trading Tracker
According to the SEC Form 4 filings, Richard S Shame has made a total of 0 transactions in Protagonist Therapeutics Inc (PTGX) over the past 5 years. The most-recent trade in Protagonist Therapeutics Inc is the sale of 657 shares on March 1, 2019, which brought Richard S Shame around $5,276.
Insider Trading History of Richard S Shame
- 1
Richard S Shame Trading Performance
Richard S Shame Ownership Network
Ownership Network List of Richard S Shame
Ownership Network Relation of Richard S Shame
Richard S Shame Owned Company Details
What does Protagonist Therapeutics Inc do?
Who are the key executives at Protagonist Therapeutics Inc?
Richard S Shame is the Chief Medical Officer of Protagonist Therapeutics Inc. Other key executives at Protagonist Therapeutics Inc include Chief Financial Officer Asif Ali , director & President and CEO Patel Dinesh V Ph D , and Chief Development Officer Suneel Gupta .
Protagonist Therapeutics Inc (PTGX) Insider Trades Summary
Over the past 18 months, Richard S Shame made no insider transaction in Protagonist Therapeutics Inc (PTGX). Other recent insider transactions involving Protagonist Therapeutics Inc (PTGX) include a net sale of 165,000 shares made by Patel Dinesh V Ph D , a net sale of 36,975 shares made by William D. Waddill , and a net sale of 39,624 shares made by Asif Ali .
In summary, during the past 3 months, insiders sold 22,203 shares of Protagonist Therapeutics Inc (PTGX) in total and bought 0 shares, with a net sale of 22,203 shares. During the past 18 months, 248,447 shares of Protagonist Therapeutics Inc (PTGX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 248,447 shares.
Protagonist Therapeutics Inc (PTGX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Protagonist Therapeutics Inc Insider Transactions
Richard S Shame Mailing Address
Above is the net worth, insider trading, and ownership report for Richard S Shame. You might contact Richard S Shame via mailing address: C/o Protagonist Therapeutics, Inc., 521 Cottonwood Drive, Suite 100, Milpitas Ca 95035.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
